Literature DB >> 18644854

Genetic research in schizophrenia: new tools and future perspectives.

Lars Bertram1.   

Abstract

Genetically, schizophrenia is a complex disease whose pathogenesis is likely governed by a number of different risk factors. While substantial efforts have been made to identify the underlying susceptibility alleles over the past 2 decades, they have been of only limited success. Each year, the field is enriched with nearly 150 additional genetic association studies, each of which either proposes or refutes the existence of certain schizophrenia genes. To facilitate the evaluation and interpretation of these findings, we have recently created a database for genetic association studies in schizophrenia ("SzGene"; available at http://www.szgene.org). In addition to systematically screening the scientific literature for eligible studies, SzGene also reports the results of allele-based meta-analyses for polymorphisms with sufficient genotype data. Currently, these meta-analyses highlight not only over 20 different potential schizophrenia genes, many of which represent the "usual suspects" (eg, various dopamine receptors and neuregulin 1), but also several that were never meta-analyzed previously. All the highlighted loci contain at least one variant showing modest (summary odds ratios approximately 1.20 [range 1.06-1.45]) but nominally significant risk effects. This review discusses some of the strengths and limitations of the SzGene database, which could become a useful bioinformatics tool within the schizophrenia research community.

Entities:  

Mesh:

Year:  2008        PMID: 18644854      PMCID: PMC2632466          DOI: 10.1093/schbul/sbn079

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  26 in total

1.  Replication validity of genetic association studies.

Authors:  J P Ioannidis; E E Ntzani; T A Trikalinos; D G Contopoulos-Ioannidis
Journal:  Nat Genet       Date:  2001-11       Impact factor: 38.330

2.  PBAT: tools for family-based association studies.

Authors:  Christoph Lange; Dawn DeMeo; Edwin K Silverman; Scott T Weiss; Nan M Laird
Journal:  Am J Hum Genet       Date:  2004-02       Impact factor: 11.025

3.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease.

Authors:  Kirk E Lohmueller; Celeste L Pearce; Malcolm Pike; Eric S Lander; Joel N Hirschhorn
Journal:  Nat Genet       Date:  2003-01-13       Impact factor: 38.330

4.  Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits.

Authors:  S Purcell; S S Cherny; P C Sham
Journal:  Bioinformatics       Date:  2003-01       Impact factor: 6.937

5.  Assessing the probability that a positive report is false: an approach for molecular epidemiology studies.

Authors:  Sholom Wacholder; Stephen Chanock; Montserrat Garcia-Closas; Laure El Ghormli; Nathaniel Rothman
Journal:  J Natl Cancer Inst       Date:  2004-03-17       Impact factor: 13.506

Review 6.  Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective.

Authors:  Rudolph E Tanzi; Lars Bertram
Journal:  Cell       Date:  2005-02-25       Impact factor: 41.582

7.  A genome-wide association study in 574 schizophrenia trios using DNA pooling.

Authors:  G Kirov; I Zaharieva; L Georgieva; V Moskvina; I Nikolov; S Cichon; A Hillmer; D Toncheva; M J Owen; M C O'Donovan
Journal:  Mol Psychiatry       Date:  2008-03-11       Impact factor: 15.992

Review 8.  The genetics of adult-onset neuropsychiatric disease: complexities and conundra?

Authors:  James L Kennedy; Lindsay A Farrer; Nancy C Andreasen; Richard Mayeux; Peter St George-Hyslop
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

9.  Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies.

Authors:  Patrick F Sullivan; Kenneth S Kendler; Michael C Neale
Journal:  Arch Gen Psychiatry       Date:  2003-12

10.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia.

Authors:  Cathryn M Lewis; Douglas F Levinson; Lesley H Wise; Lynn E DeLisi; Richard E Straub; Iiris Hovatta; Nigel M Williams; Sibylle G Schwab; Ann E Pulver; Stephen V Faraone; Linda M Brzustowicz; Charles A Kaufmann; David L Garver; Hugh M D Gurling; Eva Lindholm; Hilary Coon; Hans W Moises; William Byerley; Sarah H Shaw; Andrea Mesen; Robin Sherrington; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler; Jesper Ekelund; Tiina Paunio; Jouko Lönnqvist; Leena Peltonen; Michael C O'Donovan; Michael J Owen; Dieter B Wildenauer; Wolfgang Maier; Gerald Nestadt; Jean-Louis Blouin; Stylianos E Antonarakis; Bryan J Mowry; Jeremy M Silverman; Raymond R Crowe; C Robert Cloninger; Ming T Tsuang; Dolores Malaspina; Jill M Harkavy-Friedman; Dragan M Svrakic; Anne S Bassett; Jennifer Holcomb; Gursharan Kalsi; Andrew McQuillin; Jon Brynjolfson; Thordur Sigmundsson; Hannes Petursson; Elena Jazin; Tomas Zoëga; Tomas Helgason
Journal:  Am J Hum Genet       Date:  2003-06-11       Impact factor: 11.025

View more
  12 in total

1.  Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Authors:  Colm M P O'Tuathaigh; Brian P Kirby; Paula M Moran; John L Waddington
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

Review 2.  A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health.

Authors:  Jean-Martin Beaulieu
Journal:  J Psychiatry Neurosci       Date:  2012-01       Impact factor: 6.186

Review 3.  MicroRNA dysregulation in psychiatric disease.

Authors:  Brooke H Miller; Claes Wahlestedt
Journal:  Brain Res       Date:  2010-03-18       Impact factor: 3.252

Review 4.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

5.  Association between the G1001C polymorphism in the GRIN1 gene promoter and schizophrenia in the Iranian population.

Authors:  Hamid Galehdari; Atefeh Pooryasin; Alimohammad Foroughmand; Setareh Daneshmand; Mostafa Saadat
Journal:  J Mol Neurosci       Date:  2008-09-16       Impact factor: 3.444

6.  Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.

Authors:  Donald C Goff
Journal:  World Psychiatry       Date:  2013-06       Impact factor: 49.548

7.  The genetic validation of heterogeneity in schizophrenia.

Authors:  Atsushi Tsutsumi; Stephen J Glatt; Tetsufumi Kanazawa; Seiya Kawashige; Hiroyuki Uenishi; Akira Hokyo; Takao Kaneko; Makiko Moritani; Hiroki Kikuyama; Jun Koh; Hitoshi Matsumura; Hiroshi Yoneda
Journal:  Behav Brain Funct       Date:  2011-10-07       Impact factor: 3.759

8.  Schizophrenia genomics and proteomics: are we any closer to biomarker discovery?

Authors:  Shaheen E Lakhan; Alon Kramer
Journal:  Behav Brain Funct       Date:  2009-01-07       Impact factor: 3.759

9.  In Silico Repositioning of Dopamine Modulators with Possible Application to Schizophrenia: Pharmacophore Mapping, Molecular Docking and Molecular Dynamics Analysis.

Authors:  Melissa Mejia-Gutierrez; Bryan D Vásquez-Paz; Leonardo Fierro; Julio R Maza
Journal:  ACS Omega       Date:  2021-06-01

10.  5-Hydroxytryptamine (serotonin) 2A receptor gene polymorphism is associated with schizophrenia.

Authors:  Subash Padmajeya Sujitha; Asha Nair; Moinak Banerjee; Srinivasan Lakshmanan; Sampth Harshavaradhan; Soosiah Gunasekaran; Anilkumar Gopinathan
Journal:  Indian J Med Res       Date:  2014-12       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.